IL316281A - Methods for treating neuroinflammatory conditions - Google Patents

Methods for treating neuroinflammatory conditions

Info

Publication number
IL316281A
IL316281A IL316281A IL31628124A IL316281A IL 316281 A IL316281 A IL 316281A IL 316281 A IL316281 A IL 316281A IL 31628124 A IL31628124 A IL 31628124A IL 316281 A IL316281 A IL 316281A
Authority
IL
Israel
Prior art keywords
alkyl
membered
halo
disease
oxo
Prior art date
Application number
IL316281A
Other languages
English (en)
Hebrew (he)
Original Assignee
Athira Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athira Pharma Inc filed Critical Athira Pharma Inc
Publication of IL316281A publication Critical patent/IL316281A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL316281A 2022-05-04 2023-05-03 Methods for treating neuroinflammatory conditions IL316281A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263338328P 2022-05-04 2022-05-04
US202263414111P 2022-10-07 2022-10-07
US202263424352P 2022-11-10 2022-11-10
US202363447432P 2023-02-22 2023-02-22
PCT/US2023/020832 WO2023215377A1 (en) 2022-05-04 2023-05-03 Methods of treating neuroinflammatory conditions

Publications (1)

Publication Number Publication Date
IL316281A true IL316281A (en) 2024-12-01

Family

ID=86693083

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316281A IL316281A (en) 2022-05-04 2023-05-03 Methods for treating neuroinflammatory conditions

Country Status (10)

Country Link
US (1) US20250275976A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518865A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515045A (cg-RX-API-DMAC7.html)
KR (1) KR20250005230A (cg-RX-API-DMAC7.html)
CN (1) CN119156217A (cg-RX-API-DMAC7.html)
AU (1) AU2023263997A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248640A1 (cg-RX-API-DMAC7.html)
IL (1) IL316281A (cg-RX-API-DMAC7.html)
TW (1) TW202406554A (cg-RX-API-DMAC7.html)
WO (1) WO2023215377A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025538382A (ja) * 2022-11-18 2025-11-28 アティラ・ファーマ・インコーポレイテッド 炎症病態を治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO2004035587A1 (en) * 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US20140094413A1 (en) 2012-04-02 2014-04-03 Washington State University Hepatocyte growth factor (hgf) mimics as therapeutic agents
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
AU2021371026A1 (en) * 2020-11-02 2023-06-15 LeonaBio, Inc. Bicyclic compounds and uses thereof for the treatment of diseases
IL313039A (en) * 2021-12-17 2024-07-01 Athira Pharma Inc Uses of bicyclic compounds for the treatment of diseases

Also Published As

Publication number Publication date
CA3248640A1 (en) 2023-11-09
AU2023263997A1 (en) 2024-10-24
US20250275976A1 (en) 2025-09-04
CN119156217A (zh) 2024-12-17
WO2023215377A1 (en) 2023-11-09
TW202406554A (zh) 2024-02-16
EP4518865A1 (en) 2025-03-12
KR20250005230A (ko) 2025-01-09
JP2025515045A (ja) 2025-05-13

Similar Documents

Publication Publication Date Title
US20240352031A1 (en) Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto
JP7208931B2 (ja) Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類
AU2016353446B2 (en) Ion channel inhibitory compounds, pharmaceutical formulations and uses
ES2670571T3 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B
JP2022532706A5 (cg-RX-API-DMAC7.html)
JP7281822B2 (ja) 細菌の排出ポンプ阻害剤
JOP20230235A1 (ar) عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون
JP2016506959A5 (cg-RX-API-DMAC7.html)
JP2019505541A5 (cg-RX-API-DMAC7.html)
KR20160038008A (ko) 브로모도메인 억제제로서 신규 퀴나졸리논
BR112017018832B1 (pt) Profármacos de riluzol e seu uso e composição
CA2949573C (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
RU2008134534A (ru) 3,5-ди(арилили гетероарил)изоксазолы и 1,2,4-оксадиазолы в качестве агонистов рецентора s1p1, иммунодепрессантных и противовоспалительных агентов
CA2412968A1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
CA2510534A1 (en) Compositions useful as inhibitors of protein kinases
PT2212283E (pt) Carboxamidas de n-fenil-bipirrolidina substituídas e sua utilização terapêutica
JP2013542267A5 (cg-RX-API-DMAC7.html)
HUP0201937A2 (en) Substituted 1,5-dihydropyrrol-2-on derivatives, process for producing them and pharmaceutical compositions containing them having nmda receptor antagonist effect
MXPA05000435A (es) Derivados de azabiciclo como antagonistas de receptor muscarinico.
FI3976581T3 (fi) [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat
JP2018529648A5 (cg-RX-API-DMAC7.html)
JP2023550543A5 (cg-RX-API-DMAC7.html)
RU2010148420A (ru) Производные аминопиридина
EA200900245A1 (ru) Модуляторы активности рецептора хемокина, кристалические формы и способ их получения